PPA
LXRX icon

Parametric Portfolio Associates’s Lexicon Pharmaceuticals LXRX Stock Holding History

Parametric Portfolio Associates’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$108K Sell
51,724
-32,611
-39% -$90.4K ﹤0.01% 3553
2021
Q4 		$332K Buy
84,335
+5,537
+7% +$26.9K ﹤0.01% 3243
2021
Q3 		$379K Sell
78,798
-7,048
-8% -$28.9K ﹤0.01% 3209
2021
Q2 		$394K Sell
85,846
-6,855
-7% -$33K ﹤0.01% 3176
2021
Q1 		$544K Sell
92,701
-4,207
-4% -$29.1K ﹤0.01% 3461
2020
Q4 		$331K Buy
96,908
+42,424
+78% +$80.9K ﹤0.01% 3555
2020
Q3 		$78K Buy
54,484
+3,466
+7% +$6.17K ﹤0.01% 3830
2020
Q2 		$102K Sell
51,018
-6,120
-11% -$12K ﹤0.01% 3783
2020
Q1 		$111K Buy
57,138
+35,108
+159% +$105K ﹤0.01% 3711
2019
Q4 		$91K Buy
22,030
+7,833
+55% +$30.2K ﹤0.01% 3872
2019
Q3 		$43K Buy
14,197
+478
+3% +$1.48K ﹤0.01% 3904
2019
Q2 		$86K Sell
13,719
-3,876
-22% -$23.2K ﹤0.01% 3856
2019
Q1 		$98K Sell
17,595
-1,010
-5% -$6.13K ﹤0.01% 3820
2018
Q4 		$124K Sell
18,605
-78,951
-81% -$640K ﹤0.01% 3758
2018
Q3 		$1.04M Sell
97,556
-9,914
-9% -$114K ﹤0.01% 3068
2018
Q2 		$1.29M Buy
107,470
+32,475
+43% +$332K ﹤0.01% 2925
2018
Q1 		$643K Buy
74,995
+34,710
+86% +$321K ﹤0.01% 3226
2017
Q4 		$398K Buy
+40,285
New +$419K ﹤0.01% 3440
2017
Q3 		– Sell
-11,066
Closed -$182K – 4041
2017
Q2 		$182K Buy
+11,066
New +$171K ﹤0.01% 3840
2017
Q1 		– Sell
-10,840
Closed -$150K – 3801
2016
Q4 		$150K Buy
+10,840
New +$174K ﹤0.01% 3658
2016
Q3 		– Sell
-93,039
Closed -$1.33M – 3792
2016
Q2 		$1.33M Buy
93,039
+2,024
+2% +$27.5K ﹤0.01% 2622
2016
Q1 		$1.09M Buy
91,015
+78,480
+626% +$823K ﹤0.01% 2862
2015
Q4 		$167K Sell
12,535
-4,281
-25% -$52.6K ﹤0.01% 3774
2015
Q3 		$181K Buy
+16,816
New +$184K ﹤0.01% 3115
2014
Q4 		– Sell
-1,618
Closed -$16K – 3996
2014
Q3 		$16K Buy
+1,618
New +$17.3K ﹤0.01% 3802
2014
Q2 		– Sell
-2,066
Closed -$25K – 3766
2014
Q1 		$25K Sell
2,066
-293
-12% -$3.74K ﹤0.01% 3806
2013
Q4 		$30K Buy
+2,359
New +$37.5K ﹤0.01% 3802

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's LXRX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Lexicon Pharmaceuticals (LXRX) stake by 39% in Q1 2022, selling an estimated $90.4K and leaving 51,724 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #3553.

Parametric Portfolio Associates first reported a position in LXRX in Q4 2013 and has held it in 27 quarters since. The position peaked at $1.33M in Q2 2016. 101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

  • Parametric Portfolio Associates held 51,724 shares of Lexicon Pharmaceuticals worth $108K as of Q1 2022.
  • Parametric Portfolio Associates sold 32,611 Lexicon Pharmaceuticals shares in Q1 2022, an estimated $90.4K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3553 holding.
  • Parametric Portfolio Associates first reported a position in Lexicon Pharmaceuticals in Q4 2013 and has held it in 27 quarters since.
  • Parametric Portfolio Associates's Lexicon Pharmaceuticals position peaked at $1.33M in Q2 2016.
  • 101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.